search button
Open Access

Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis

  • Authors:
    • Na He
    • Gong Feng
    • Chunyan Zhang
    • Fangxiong Wu
    • Ting Zhang
    • Yongqin Yang

  • View Affiliations

  • Published online on: July 23, 2020     https://doi.org/10.3892/mmr.2020.11356
  • Pages: 2705-2714

  • Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) was the third most common cause of cancer‑associated mortality in China in 2015. Early detection of HCC and hepatic cirrhosis (HC) can serve a crucial role in the prevention and therapeutic intervention of these diseases. Current early detection methods rely on less sensitive imaging modalities compared with the pathological examination. In the present study, a total of 64 patients with HCC, 44 patients with HC and 298 individuals with no evidence of disease (NED) were recruited, and the ability of methylated septin 9 (mSEPT9) in diagnosing HCC and HC was investigated. The overall detection sensitivity of mSEPT9 for HCC and HC was 76.7 and 34.1%, respectively, with a 95.9% specificity (HCC vs. NED). The sensitivity of mSEPT9 for HCC was significantly higher than that of α‑fetoprotein (AFP; χ2 test; 56.7%; P<0.05). The areas under the curve from the receiver operating characteristic curves of mSEPT9 for detection of HCC vs. NED, HC vs. NED and HCC vs. HC were 0.85, 0.77 and 0.66, respectively, while those of AFP for the same groups were 0.80, 0.55 and 0.77, respectively. Although both markers exhibited stage‑dependent sensitivity in HCC, mSEPT9 was demonstrated to be more sensitive than AFP. The net reclassification index of mSPET9 for HCC detection was 0.212 compared with AFP, suggesting an improved diagnostic performance of mSEPT9 compared with AFP. In addition, Kaplan‑Meier survival analysis revealed that mSEPT9 is able to predict the long‑term survival of patients with HCC. Further analysis suggested that patients >50 years of age exhibited higher sensitivity compared with those <50 years old in mSEPT9, but not in AFP. No significant difference in sensitivity was observed between compensated and decompensated patients with HC, and in patients with HC with a history of hepatitis B or C virus infection. No difference was observed between male and female subjects in the HC and HCC groups for mSEPT9 and AFP. In conclusion, mSEPT9 may detect HCC with an overall improved sensitivity compared with AFP and may help in predicting the long‑term survival of patients with HCC. The present clinical study was retrospectively registered to the Chinese Clinical Trial Registry on April 4, 2020 (http://www.chictr.org.cn/enIndex.aspx; registration no. ChiCTR2000031547).
View Figures
View References

Related Articles

Journal Cover

October-2020
Volume 22 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 6.9
  • CiteScore Rank: Q2: #98/328 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.721
  • SCImago Journal Rank (SJR): 0.65
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
He N, Feng G, Zhang C, Wu F, Zhang T and Yang Y: Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis. Mol Med Rep 22: 2705-2714, 2020
APA
He, N., Feng, G., Zhang, C., Wu, F., Zhang, T., & Yang, Y. (2020). Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis. Molecular Medicine Reports, 22, 2705-2714. https://doi.org/10.3892/mmr.2020.11356
MLA
He, N., Feng, G., Zhang, C., Wu, F., Zhang, T., Yang, Y."Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis". Molecular Medicine Reports 22.4 (2020): 2705-2714.
Chicago
He, N., Feng, G., Zhang, C., Wu, F., Zhang, T., Yang, Y."Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis". Molecular Medicine Reports 22, no. 4 (2020): 2705-2714. https://doi.org/10.3892/mmr.2020.11356